eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 59 blog entries.
31 01, 2017

Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th

Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PALO ALTO, Calif. – January 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President [...]

4 01, 2017

Eiger Completes $25 Million Debt Financing with Oxford Finance

Eiger Completes $25 Million Debt Financing with Oxford Finance PALO ALTO, Calif., January 4, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC (“Oxford”), a specialty finance firm that provides [...]

3 01, 2017

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) — First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif., January 3, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced [...]

12 12, 2016

Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)

Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) - Positive Interim Data from Phase 2 Multiple-Ascending Dose Study - Novel Liquid Formulation of Exendin 9-39 - US Orphan Designation for Hyperinsulinemic Hypoglycemia PALO ALTO, Calif., December 12, 2016 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development [...]

29 11, 2016

Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)

Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) - Exendin 9-39 investigational new drug (IND) application filed - PBH Analyst / Key Opinion Leader Event planned December 9th - Multiple-ascending dose (MAD) study interim data to be presented PALO ALTO, Calif., November 29, 2016 — Eiger BioPharmaceuticals, [...]

17 11, 2016

Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting

Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting - Update on Data Presented and Analyst Meeting through Monday Evening PALO ALTO, Calif., November 14, 2016 -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced presentation of additional data from the LOWR HDV [...]

14 11, 2016

Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program

Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program - Data Presented through Monday Morning PALO ALTO, Calif., November 14, 2016 -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced an update on presentations of [...]

8 11, 2016

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016  Eiger Hosted LOWR HDV Program Key Opinion Leader Review at AASLD 2016  Four Product Candidates in Four Orphan Indications Continuing to Advance PALO ALTO, Calif., November [...]

24 10, 2016

Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection

Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection - Collaboration with ARUP Laboratories and Hepatitis B Foundation - HDV viral load assay now available in U.S. PALO ALTO, Calif., October 24, 2016, Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a clinical-stage biopharmaceutical company focused on the development and [...]

19 10, 2016

Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection

Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection - LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., October 19, 2016 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first [...]